Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,414 across all filing types
Latest filing 2025-04-30 M&A Activity
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
M&A Activity Classification · 99% confidence The document is explicitly titled "Press Release" and announces the closing of a major transaction (sale of a stake in Opella) and its strategic implications for Sanofi. This type of announcement, detailing significant corporate events, financial proceeds, and management commentary, is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is a press release announcing a major corporate event (transaction closing and strategic shift) rather than a detailed periodic financial report (like 10-K or IR), ER is the most appropriate fit among the provided options for a primary financial results/event announcement. It is not a transcript (CT), a formal regulatory filing like 10-K, or a simple dividend notice (DIV). Given the context of major corporate news, ER is selected over the general RNS fallback.
2025-04-30 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-30 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-29 English
Sanofi : Déclaration des transactions sur actions propres
Transaction in Own Shares Classification · 100% confidence The document is titled "Déclaration des transactions sur actions propres" which translates to "Declaration of transactions on own shares." It details daily aggregated and individual transactions of Sanofi's own shares, including dates, volumes, prices, and market codes. The content focuses exclusively on share buybacks or transactions involving the company's own shares. There is no indication of financial results, management changes, voting results, or other report types. The document is not a report publication announcement or a certification but a detailed transaction report. Therefore, it fits the category of "Transaction in Own Shares" (POS). The document length is substantial (15,000 characters), supporting that it is a full transaction report rather than a brief announcement.
2025-04-28 French
Sanofi: Disclosure of trading in own shares
Transaction in Own Shares Classification · 100% confidence The document is titled 'Disclosure of trading in own shares' and details specific transactions of the company Sanofi buying back its own shares over several days in April 2025. It includes aggregated daily volumes, prices, brokers involved, and references to MAR (Market Abuse Regulation) articles, which govern share repurchases and insider trading disclosures. The content is focused on the company's repurchase activity and does not contain financial statements, earnings data, or management commentary. This matches the definition of 'Transaction in Own Shares' filings, which report on share repurchase activities. The document length is substantial and contains detailed transaction data, confirming it is the report itself, not just an announcement or certification. Therefore, the correct classification is POS (Transaction in Own Shares).
2025-04-28 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release dated April 24, 2025, about Sanofi's strong Q1 performance and confirmation of 2025 guidance. The document is relatively short (1361 characters) and primarily serves to announce the press release rather than containing detailed financial statements or comprehensive analysis. According to the rules, such filings that announce or attach a report but do not contain the full report themselves should be classified as Regulatory Filings (RNS).
2025-04-24 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.